Effects of specific post‐menopausal hormone therapies on bone mineral density in post‐menopausal women: a meta‐analysis

ISSN： 1460-2350

Source： Human Reproduction, Vol.18, Iss.8, 2003-08, pp. : 1737-1746

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

BACKGROUND: Long‐term post‐menopausal hormone therapy (pHT) was often regarded as first‐line therapy to prevent fractures in post‐menopausal women, a recommendation under scrutiny given the benefit–risk profile of the Women’s Health Initiative results of the estrogen–progestin combination. Apart from controlled clinical studies providing data with fractures as an end point, measures of lumbar and hip bone mineral density (BMD) may be used to assess bone‐related effects of pHT. The objective of this study was to conduct a systematic review of 2‐year trials, published between 1990 and December 2002, and assessing changes in BMD by any estrogen including ethinyl estradiol, any estrogen plus any progestin, or tibolone. METHODS: We searched MEDLINE, EMBASE and systematic reviews. Thirty‐nine randomized, prospective, controlled 2‐year trials were analysed in pre‐specified groups according to the profile of the compounds. RESULTS: Virtually all pHT regimens at least maintain BMD at the lumbar spine and the hip compared with baseline; there is no apparent difference between the various estrogenic compounds. Tibolone, a synthetic progestin, appears to be as effective as any estrogen. Most trials were conducted in early post‐menopausal women, fewer in women with hysterectomy and/or bilateral oophorectomy. CONCLUSIONS: The size of impact on BMD does not appear to differ between tibolone and any estrogen compound studied.